Furthermore, the blockade of CXCL12-CXCR4 axis along with anti-PD-1 and anti-CTLA-4 ICB therapies promises anti-tumour responses in colon cancer, emphasising the importance of combination therapies (144). This evidence concerns the gene PDCD1 and neoplasm.